Develops innovative treatments for breast cancer and other breast conditions using a multi-faceted approach.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, specializes in the research and development of treatments for oncology and infectious diseases. Central to its portfolio is Endoxifen, an active metabolite of tamoxifen, currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. The company's innovative pipeline also includes AT-H201, an inhalation therapy designed to enhance lung function in critically ill COVID-19 patients, and AT-301, a proprietary nasal administration drug candidate aimed at combating COVID-19. Additionally, Atossa Therapeutics is advancing immunotherapy and chimeric antigen receptor (CAR) T-cell therapy programs targeting breast cancer,, underscoring its commitment to advancing novel therapeutic options for challenging medical conditions.
Originally established as Atossa Genetics Inc. in 2008, the company rebranded to Atossa Therapeutics, Inc. in January 2020 to better reflect its expanded focus and strategic direction in pharmaceutical research. Atossa Therapeutics collaborates closely with esteemed institutions such as the Dana-Farber Cancer Institute, Inc., under a research agreement focused on cytokine-coated nanoparticles for breast cancer treatment, further bolstering its research capabilities and potential treatment innovations.
Driven by a mission to improve patient outcomes through innovative science and clinical excellence, Atossa Therapeutics continues to advance its pipeline with a strong emphasis on precision medicine and therapeutic advancements. With a dedicated team of researchers and healthcare professionals, the company remains committed to addressing critical unmet medical needs and transforming the landscape of cancer and infectious disease treatment.